WINCHESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the third quarter 2024 and provided a corporate update.
Synlogic, Inc. (SYBX) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $3.60 per share a year ago.
Synlogic (NASDAQ: SYBX ) stock is falling on Friday after the clinical-stage biopharmaceutical company announced the discontinuation of its Synpheny-3 clinical trial. According to a press release from Synlogic, this decision comes after an internal review of the clinical trial's progress.
Synlogic (NASDAQ: SYBX ) stock is sliding lower on Thursday after the biopharmaceutical company announced a reverse split for its shares. According to a press release from Synlogic, the company enacted a reverse stock split after markets closed yesterday.
CAMBRIDGE, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that Aoife Brennan, M.B. Ch.B., President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference being held in New York, NY, June 7-9, 2023.
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 7.69% and 73.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?